Two well-known active agents, Mesalamine (MES) and Sucralfate (SUC), were investigated for possible utilisation as fixed-dose combination product. The anti-inflammatory action of MES in association with bioadhesiveness and mucosal healing properties of SUC were considered promising for the development of a new compound containing both molecules, aimed as an improved treatment of ulcerative colitis. 

More